Genmab — Oktober 2017
-
How I treat myeloma with new agents Philippe Moreau - http://www.bloodjournal.org/content/bloodjournal/130/13/1507.full.pdf
-
"..the HR for PFS achieved with the DRd combination in relapsed MM in the POLLUX trial (0.37) has set the bar so high that it will be difficult to show the superiority of other combinations over DRd in phase III trials designed for regula
tory approvals." -
Bare så jeg også forstår det
Vil fordelen for Genmab med smoldering være at behandlingstiden vil forøges markant, eller vil det være kursdrivende, fordi at der vil være flere patienter, eller en kombi heraf... -
Kan vi stadig se frem til 2 IND'er her i Q4, eller hvordan ligger landet
-
Dog ikke så store udsving som tidligere.....ser ud som om A/B holder sig nogenlunde på måtten -:)
-
JV - hvis man ser på slide 16, så må svaret være ja
http://files.shareholder.com/downloads/AMDA-KPIBN/138540251x7895654x956779/5BB3036D-BB67-4C1F-A273-265DD2A1F676/Investor_prestn_September_v080917v2.pdf -
Det har været lidt udfordrende at være i Bull.
-
Tak GB. Præsentationen er fra sep 2017, så de må mene det alvorligt
-
For at vende tilbage til tidligere i dag ang. blogbuster.nl. Jeg er ikke på dette site. Er der nogen her der er og hvad er det de debatterer ang. Genmab?
-
Blot en kort opsumering.
..på forhånd tak. -
Så er der gang i warrants igen igen. https://globenewswire.com/news-release/2017/10/05/1141601/0/en/Grant-of-Restricted-Stock-Units-and-Warrants-to-Genmab-employees.html
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind